J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halstenson, C.
Right arrow Articles by Pan, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halstenson, C.
Right arrow Articles by Pan, H
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment

CE Halstenson, J Triscari, A DeVault, B Shapiro, W Keane, and H Pan

The disposition of a single 20-mg oral dose of pravastatin was assessed in subjects with various degrees of renal function. Sixteen subjects (13 males, 3 females) with creatinine clearance values ranging from 15 to 112 mL/min/1.73 m2 completed the study. Area under the serum concentration-time curve, maximum serum concentration, time to maximum serum concentration, terminal serum elimination half-life, apparent clearance, and apparent volume of distribution for pravastatin were not affected by renal impairment, whereas the renal clearance of pravastatin decreased as creatinine clearance decreased (r2 = 0.697, P less than .001). The area under the serum concentration-time curve and time to maximum serum concentration of SQ 31,945 (a hepatic metabolite) increased in patients with renal impairment, whereas the terminal elimination rate constant and renal clearance of SQ 31,945 significantly decreased as a function of creatinine clearance. The renal clearance of another metabolite (SQ 31,906) also significantly declined with decreasing renal function. This single-dose study demonstrates that pravastatin pharmacokinetics were not affected in patients with renal impairment, probably because of its dual route of elimination.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 VASC ENDOVASCULAR SURGHome page
R. H. Samson
The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Vascular and Endovascular Surgery, August 1, 2008; 42(4): 352 - 366.
[Abstract] [PDF]

Home page
 BMJHome page
G. F M Strippoli, S. D Navaneethan, D. W Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and J. C Craig
Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
BMJ, March 22, 2008; 336(7645): 645 - 651.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Tonelli, L. Moye, F. M. Sacks, T. Cole, and G. C. Curhan
Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease
J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1605 - 1613.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
M. Tonelli, L. Moye, F. M. Sacks, B. Kiberd, G. Curhan, and for the Cholesterol and Recurrent Events (CARE) Tr
Pravastatin for Secondary Prevention of Cardiovascular Events in Persons with Mild Chronic Renal Insufficiency
Ann Intern Med, January 21, 2003; 138(2): 98 - 104.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American College of Clinical Pharmacology